RECURSION PHARMACEUTICALS-A (RXRX)
US75629V1044 - Common Stock
RECURSION PHARMACEUTICALS-A
NASDAQ:RXRX (4/23/2024, 3:34:20 PM)
After market: 7.75 +0.05 (+0.65%)7.7
+0.1 (+1.32%)
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 500 full-time employees. The company went IPO on 2021-04-16. The company is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. The Company’s platform, Recursion Operating System (OS), is built with diverse technologies and enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The company integrates physical and digital components as iterative loops of atoms and bits of wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of cerebral cavernous malformation (CCM). REC-2282 is developed for the treatment of neurofibromatosis type 2.
Company Info
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101
P: 13852690203
CEO: Christopher Gibson
Employees: 500
Website: https://www.recursion.com/
RXRX News
6 days ago - The Motley FoolWhere Will Recursion Pharmaceuticals Be in 5 Years?A lot is riding on whether its platform is valuable, or vaporware.
7 days ago - Recursion Pharmaceuticals, Inc.Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerDr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also...
8 days ago - InvestorPlaceBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialWith the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
8 days ago - InvestorPlaceWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024Through opportunity for growth and strong financial performance, these three Cathie Wood stocks could provide generous returns.
13 days ago - The Motley FoolCan Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.Recursion is playing the long game with its AI-focused approach to drug discovery and development.
RXRX Twits
Here you can normally see the latest stock twits on RXRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
